Chronic obstructive pulmonary disease (COPD) is a debilitating condition that obstructs airflow in the lungs, making it difficult for patients to breathe. Traditional treatments often fall short in effectively opening obstructed bronchi and bronchioles. This patent introduces an innovative endobronchial telescopic catheter designed to address these challenges by combining mechanical and biological solutions. The core feature of this invention is its ability to deliver stem cell fluid enriched with Platelet Rich Plasma (PRP) directly to the affected areas in the lungs. The catheter comprises multiple segments, each equipped with balloons that can be rhythmically inflated and deflated to clear obstructions and facilitate the delivery of therapeutic agents.
The inventive step lies in the catheter's telescopic design and its integration of PRP therapy, which is novel in the context of COPD treatment. This approach not only mechanically opens the airways but also promotes tissue regeneration through stem cell therapy. The benefits are significant: improved breathing, reduced symptoms, and potentially enhanced lung function for patients.
Broader impacts include advancing COPD treatment, reducing healthcare costs associated with chronic management, and improving patient quality of life. This invention could revolutionize respiratory therapies by offering a more effective and holistic approach to treating obstructive lung diseases.